Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK8527-007)


A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8527 Once Monthly in Participants at Low Risk for HIV-1 Infection

The purpose of this study is to assess the safety and tolerance of MK-8527 administered once monthly at doses of 3 mg, 6 mg, and 12 mg throughout the treatment period and until the final follow-up visit. The study will specifically examine:

  • Adverse events experienced by participants.
  • Adverse events that result in the discontinuation of the study intervention.


Dr Nicole Poovan (Primary Investigator)

Latest Update

April 2024

For more details about MK8527-007 please email

Click here for further details regarding the MK8527-007 study.

Stay up to date

Get updates on news, resources, events and happenings from Wits RHI.